Pharmacotherapeutic approaches to treating depression during the perimenopause

@article{Garay2019PharmacotherapeuticAT,
  title={Pharmacotherapeutic approaches to treating depression during the perimenopause},
  author={Ricardo P Garay and Thomas Charpeaud and Susan Jane Sinclair Logan and Patrick Hannaert and Raul G Garay and Pierre Michel Llorca and Shefaly Shorey},
  journal={Expert Opinion on Pharmacotherapy},
  year={2019},
  volume={20},
  pages={1837 - 1845}
}
ABSTRACT Introduction: Although postnatal depression is now well recognized, there is also a risk of depressive symptoms during perimenopause. The mechanisms underlying perimenopausal depression are still poorly understood; however, there are available treatment options. Areas covered: This review describes: the current pharmacotherapeutic approaches for perimenopausal depression, their strengths and weakness, and provides recommendations on how current treatment can be improved in the future… 

Novel drug developmental strategies for treatment‐resistant depression

Novel drug targets and drug candidates currently investigated in Phase I–III clinical trials, including inhibition of glutamatergic neurotransmission by NMDA and mGlu5 receptors, modulation of the opioidergic system by κ receptor antagonists, and hallucinogenic tryptamine derivates are reviewed.

Menopausal Hormone Therapy and the Mind: The Role of Hormone Replacement in the Prevention and Treatment of Cognitive Decline, Dementia, and Cognitive Dysfunction of Depression

The neurobiological effects of MHT are synthesized, recommendations for its use in current clinical practice in the contexts of cognitive dysfunction associated with major depressive disorder, cognitive decline, and Alzheimer’s disease are made, and the frontiers being explored by ongoing research on this topic are discussed.

Pharmacogenetic and drug interaction aspects on ketamine safety in its use as antidepressant ‐ implications for precision dosing in a global perspective

Taking a look at individual patient risks and potential underlying variability in pharmacokinetics may improve safety and dosing of these new antidepressant drugs in clinical practice.

Stimulated Parotid Saliva Is a Better Method for Depression Prediction

Saliva collection methods point to an exciting opportunity for non-invasive monitoring of cortisol through saliva to explore the application value of saliva cortisol in depression prediction.

HRP_220057 215..225

  • 2022

References

SHOWING 1-10 OF 105 REFERENCES

Guidelines for the Evaluation and Treatment of Perimenopausal Depression: Summary and Recommendations.

An expert panel was convened to systematically review the published literature and develop guidelines on the evaluation and management of perimenopausal depression, finding that most midlife women who experience a major depressive episode during the perimenopause have experienced a prior episode of depression.

EFFICACY OF ESTRADIOL IN PERIMENOPAUSAL DEPRESSION: SO MUCH PROMISE AND SO FEW ANSWERS

Methodologic differences of note include menopausal state (perimenopause vs. postmenopause), determination of state (earlier studies used age as a proxy measure), baseline symptomatology (asymptomatic vs. depressive symptoms vs. syndromic depression), route of hormone administration (transdermal vs. oral), and symptom or syndrome measure.

A Multicenter, Randomized, Controlled Trial of Electroacupuncture for Perimenopause Women with Mild-Moderate Depression

EA treatment is effective and safe in relieving depression symptom and improving the quality of life in the perimenopause depression, and the mechanism of this intervention is still unclear.

Assessment of perimenopausal depression: A review.

Depressive Symptoms in the Perimenopause: Prevalence, Assessment, and Guidelines for Treatment

It is found that a positive association may exist between depressive symptoms and the perimenopause, and that a prior history of depression may be associated with such symptoms.

Effects of Estradiol Withdrawal on Mood in Women With Past Perimenopausal Depression: A Randomized Clinical Trial.

In women with past PMD that was previously responsive to hormone therapy, the recurrence of depressive symptoms during blinded hormone withdrawal suggests that normal changes in ovarian estradiol secretion can trigger an abnormal behavioral state in these susceptible women.

Investigational drugs in recent clinical trials for treatment-resistant depression

The authors describe the medications for treatment-resistant depression (TRD) in phase II/III of clinical development in the EU and USA and provide an opinion on how current treatment can be improved in the near future.

Depression or menopause? Presentation and management of major depressive disorder in perimenopausal and postmenopausal women.

  • A. ClaytonP. Ninan
  • Medicine, Psychology
    Primary care companion to the Journal of clinical psychiatry
  • 2010
Routine screening of this at-risk population followed by careful assessment for depressive symptoms can help identify the presence of MDD in the menopausal transition.

Estrogen augmentation of antidepressants in perimenopausal depression: a pilot study.

Short-term, low-dose estrogen augmentation of antidepressant medication was significantly associated with improved mood, but not memory, in perimenopausal women with MDD in partial remission.
...